{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06453460",
            "orgStudyIdInfo": {
                "id": "4005"
            },
            "secondaryIdInfos": [
                {
                    "id": "UCI 22-188",
                    "type": "OTHER",
                    "domain": "UCI"
                }
            ],
            "organization": {
                "fullName": "University of California, Irvine",
                "class": "OTHER"
            },
            "briefTitle": "Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla",
            "officialTitle": "Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letermovir Prophylaxis After Allogeneic Hematopoietic Cell Transplantation",
            "therapeuticArea": [
                "Other"
            ],
            "study": "prospect-eval-of-efficacy-of-cmv-tcip-direct-letermovir-prophylax-after-allogen-hemato-cell-transpla"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-05",
            "studyFirstSubmitQcDate": "2024-06-05",
            "studyFirstPostDateStruct": {
                "date": "2024-06-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Piyanuch Kongtim",
                "investigatorTitle": "Associate Clinical Professor",
                "investigatorAffiliation": "University of California, Irvine"
            },
            "leadSponsor": {
                "name": "University of California, Irvine",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eurofins Viracor",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor."
        },
        "conditionsModule": {
            "conditions": [
                "CMV",
                "Allogeneic Stem Cell Transplantation"
            ],
            "keywords": [
                "CMV T Cell Immunity Panel",
                "CMV reactivation",
                "Allogeneic stem cell transplantation",
                "Letermovir"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AHCT recipients",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Letermovir",
                        "Device: CMV T Cell Immunity Panel (CMV-TCIP)",
                        "Diagnostic Test: CMV DNA PCR"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Letermovir",
                    "description": "Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.",
                    "armGroupLabels": [
                        "AHCT recipients"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "CMV T Cell Immunity Panel (CMV-TCIP)",
                    "description": "Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.",
                    "armGroupLabels": [
                        "AHCT recipients"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "CMV DNA PCR",
                    "description": "Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.",
                    "armGroupLabels": [
                        "AHCT recipients"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Cumulative incidence of clinically significant cytomegalovirus infection (CS-CMVi) at 52 weeks after transplant",
                    "description": "Number of patients who develop CS-CMVi within 52 weeks after receiving a transplant",
                    "timeFrame": "1 year after transplant"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cumulative incidence of CMV disease at 52 weeks after transplant",
                    "description": "Number of patients who develop CMV disease within 52 weeks after receiving a transplant",
                    "timeFrame": "1 year after transplant"
                },
                {
                    "measure": "Cumulative incidence of CMV related death at 52 weeks",
                    "description": "Number of patients who die from complications directly attributable to CMV infection within 52 weeks",
                    "timeFrame": "1 year after transplant"
                },
                {
                    "measure": "Overall Survival at 1 year after transplant",
                    "description": "Number of patients who survive beyond 1 year after transplant",
                    "timeFrame": "1 year after transplant"
                },
                {
                    "measure": "Positive predictive value of CMV-TCIP assay after transplant in predicting CS-CMVi protection",
                    "description": "Positive predictive value of CMV-TCIP assay at 14 weeks after transplant in predicting CS-CMVi protection through 1 year after transplant in patients who had letermovir discontinuation",
                    "timeFrame": "1 year after transplant"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \u2265 18 years of age on the day of signing informed consent.\n* Karnofsky performance \\>70%\n* Have documented seropositivity for CMV (either donor or recipient CMV IgG seropositivity) before AHCT.\n* Eligible for AHCT from an HLA-matched related, matched unrelated, mismatched unrelated or haploidentical donor using either bone marrow or peripheral blood stem cells.\n* Have undetectable CMV DNA from a plasma sample collected within 5 days prior to enrollment.\n* Be within 28 days post-HSCT at the time of enrollment.\n* Be able to comply with medical recommendations or follow-up.\n* Has adequate organ functions determined by\n\n  1. Serum creatinine clearance \u226550 ml/min (calculated with Cockroft-Gault formula).\n  2. Bilirubin \u22641.5 mg/dl except for Gilbert's disease.\n  3. ALT or AST \u2264200 IU/ml for adults.\n  4. Conjugated (direct) bilirubin \\< 2x upper limit of normal.\n  5. Left ventricular ejection fraction \u226540%.\n  6. Diffusing capacity for carbon monoxide (DLCO) \u2265 50% predicted corrected for hemoglobin.\n\nExclusion Criteria:\n\n* Has a history of CMV end-organ disease or CS-CMVi within 6 months prior to enrollment.\n* Received within 7 days prior to screening or plans to receive during the study any of the following:\n\n  1. Ganciclovir\n  2. Valganciclovir\n  3. Foscarnet\n  4. Acyclovir (\\> 3200 mg PO per day or \\> 25 mg/kg IV per day)\n  5. Valacyclovir (\\> 3000 mg/day)\n  6. Famciclovir (\\> 1500 mg/day)\n* Received within 30 days prior to screening or plans to receive during the study any of the following drugs: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent/biologic therapy.\n* Has suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations.\n* Has an uncontrolled infection on the day of randomization.\n* Requires mechanical ventilation or is hemodynamically unstable at the time of randomization.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Chao Family Comprehensive Cancer Center University of California, Irvine",
                    "role": "CONTACT",
                    "phone": "1-877-827-8839",
                    "email": "ucstudy@uci.edu"
                },
                {
                    "name": "University of California Irvine Medical",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Piyanuch Kongtim, MD,PhD",
                    "affiliation": "Chao Family Comprehensive Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Chao Family Comprehensive Cancer Center, University of California Irvine",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Piyanuch Kongtim, MD, PhD",
                            "role": "CONTACT",
                            "phone": "877-827-8839",
                            "email": "ucstudy@uci.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000588473",
                    "term": "Letermovir"
                }
            ],
            "ancestors": [
                {
                    "id": "D000067856",
                    "term": "Poly(ADP-ribose) Polymerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M233992",
                    "name": "Letermovir",
                    "asFound": "Low-fat diet",
                    "relevance": "HIGH"
                },
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}